# **Confluence Duplex Guidelines**

Based on ESVS Carotid Guidelines 2017 and 2023, ASA/ACCF/AANN/SIR/SVS carotid guidelines 2011 and 2022, SVS PAD guidelines 2015 and 2019, SVS AAA guidelines 2017, SVS imaging guidelines 2018, communication with Dr Moneta, various articles

# Contents

Carotid disease:2
Screening:2
Symptomatic (focal hemispheric symptoms, sudden vertigo):2
Asymptomatic:
Surveillance:
After carotid endarterectomy:3
After carotid stent:
Aortic aneurysm:4
Screening:4
Surveillance:4
Post-EVAR:
Post-open repair5
TEVAR:
Thoracic aortic aneurysm:5
Thoracic Dissection:
Blunt Aortic Injury:
Open thoracic aneurysm repair:5
Peripheral Arterial Disease:
Screening:5
Surveillance after bypass:
Aortibifemoral bypass:
lliofemoral bypass:6
Femoral-femoral bypass:6
Axillobifemoral bypass:6
Infrainguinal bypass with PTFE:6
Infrainguinal bypass with vein:6
Surveillance after angioplasty or stent:

Aortoiliac segment:
Femoropopliteal segment:6
Tibial segment:6
Mesenteric disease:
Screening:7
Surveillance after angioplasty, stent, or bypass:7
Renal artery stenosis:7
Screening:7
Surveillance after renal artery angioplasty, stent, endarterectomy, bypass:7

# Carotid disease:

#### Screening:

Symptomatic (focal hemispheric symptoms, sudden vertigo):

Immediate (current guidelines are for the patient to go to the ER for evaluation and work-up)

NB:

Almost no dizziness is due to cerebrovascular disease. Recommend excellent guidelines from the American Academy of Family Practitioners:

#### https://www.aafp.org/pubs/afp/issues/2017/0201/p154.html

#### Asymptomatic:

Prevalence of asymptomatic carotid stenosis >70% (when we would think about surgery) is **0.5%** of the general population. Guidelines recommend AGAINST screening the general population.

2 reasons to order a duplex if **no** symptoms are present:

- 1. To optimize medical management
- 2. Consider a patient for surgery for stroke risk reduction. If this is the case, then the patient needs to be a good surgical candidate and expected to live at least 5 years

Duplex NOT indicated for bruit alone (VERY low prevalence of a significant carotid stenosis), only if other atherosclerotic risk factors are present

Screening is most cost effective in a high risk population.

To make a screening worth the cost of the duplex, the patient should have at least **2** of the following risk factors (preferably more):

Age >60

Hypertension

Coronary artery disease

Current smoking

Peripheral arterial disease

History of a stroke

1<sup>st</sup> degree relative with a prior stroke

1<sup>st</sup> degree relative with atherosclerosis before age 60

#### Surveillance:

Once a stenosis in found in an **asymptomatic** patient:

Follow-up duplexes only indicated if stenosis is >50%

50-69% stenosis: annual, "if stability has been established over an extended period or the patient's candidacy for further intervention has changed, longer intervals or termination of surveillance may be appropriate"

>70% stenosis: every 6 months until stable, then every year (especially if "risk factors" controlled like diabetes and smoking)

#### After carotid endarterectomy:

Duplex within 3 months of the surgery, then every 6 months x 2 years, then annually x2 years until stable.

If stable, then duplex every 2 years

If progression, then every 6-12 months depending on scenario

#### After carotid stent:

For most patients:

Duplex within 3 months of the stent, then every 6 months x 2 years, then annually x2 years until stable.

If stable, then duplex every 2 years

If progression, then every 6-12 months depending on scenario

For patients with diabetes, aggressive in-stent restenosis (type IV – diffuse proliferative), prior treatment for in-stent restenosis, prior cervical radiation, or heavy calcification:

Duplex within 3 months of stent, then duplex every 6 months until stable clinical pattern is established and then annually thereafter.

## Aortic aneurysm:

#### Screening:

One time ultrasound screening in men or woman ages 65-75 with a history of tobacco use

One time screening in men or women ages 65-75 with a first degree relative with AAA.

Consideration can be given to screening a patient >75 if in good health

#### Surveillance:

If aortic diameter >2.5 but <3cm: rescreen in 10 years (if appropriate based on age and health)

If aortic diameter 3-3.9cm: imaging every 3 years

If aortic diameter is 4.0-4.9cm: imaging every 12 months

If aortic diameter 5.0-5.4cm: imaging every 6 months, please consider Vascular surgery referral at this size if patient is a good surgical candidate

If aortic diameter 5.5cm and above, please consider consider Vascular surgery referral at this size if patient is a good surgical candidate

#### Post-EVAR:

Baseline imaging in the first month after EVAR with CTA AND duplex – if no endoleak or sac enlargement, then another CTA AND duplex at 12 months (non-contrast CT if contraindication to contrast).

After first year, if stable without leak, annual follow-up with CTA OR duplex (preferably duplex)

If type II endoleak seen within first month after EVAR, then they need a CTA AND duplex at 6 months

If type II endoleak after 6 months is associated with a shrinking/stable sac size, then duplexes every 6 months x 2 years and annually thereafter

Type I and III leaks receive additional contrast imaging and repair

Total aortic imaging with non-contrast CT scan every 5 years

Post-open repair Total aortic imaging with non-contrast CT scan every 5 years

#### TEVAR:

Thoracic aortic aneurysm: CTA at 1 month and 12 months after surgery and then annually

If abnormality at 1 month, then imaging at 6 months

#### Thoracic Dissection:

CTA at 1 month, 6 months, and 12 months, then annually if stable

#### Blunt Aortic Injury:

CTA at 1 month and 12 months, then annually if stable

If abnormality at 1 month, then imaging at 6 months

#### Open thoracic aneurysm repair:

CT imaging with or without contrast every 5 years

## Peripheral Arterial Disease:

#### Screening:

Signs or symptoms of the disease (claudication or critical limb ischemia)

As a screening measure in patients with risk factors for medical management, risk stratification, and preventative care

NB: if patient has non-healing ulcer or gangrene, please schedule ABI urgently

NB: vascular claudication (leg pain with walking) presents stereotypically. If you have questions about whether a patient's symptoms may be vascular, please contact the vascular surgeons.

#### Surveillance after bypass:

#### Aortibifemoral bypass:

Clinical examination and ABI with or without addition of duplex in early post-op period, then at 6 months and 12 months. Continue exam and ABI with or without duplex annually unless new symptoms.

#### Iliofemoral bypass:

Clinical examination and ABI with or without addition of duplex in early post-op period, then at 6 months and 12 months. Continue exam and ABI with or without duplex annually unless new symptoms.

#### Femoral-femoral bypass:

Clinical examination and ABI with or without addition of duplex in early post-op period, then at 6 months and 12 months. Continue exam and ABI with or without duplex annually unless new symptoms.

#### Axillobifemoral bypass:

Clinical examination and ABI with or without addition of duplex in early post-op period, then at 6 months and 12 months. Continue exam and ABI with or without duplex annually unless new symptoms.

#### Infrainguinal bypass with PTFE:

Clinical examination and ABI with or without addition of duplex in early post-op period, then at 6 months and 12 months. Continue exam and ABI with or without duplex annually unless new symptoms.

#### Infrainguinal bypass with vein:

Clinical examination with ABI AND duplex ultrasound in the early post-operative period, then at 3 months, 6 months, and 12 months. Follow-up at least annually.

More frequent surveillance after one year if uncorrected abnormalities exist.

More frequent imaging also indicated if alternative vein conduits (other than great saphenous vein) are used.

# Surveillance after angioplasty or stent:

#### Aortoiliac segment:

Clinical examination, ABI, and DUS within first month. Clinical examination and ABI with or without DUS at 6 months and 12 months, and then annually as long as there are no new signs or symptoms.

#### Femoropopliteal segment:

Clinical examination, ABI, and DUS within first month.

Continued surveillance at 3 months and then every 6 months if:

A stent was placed

Patients with critical limb ischemia because of an increased risk of recurrent critical limb ischemia should the intervention fail

#### Tibial segment:

Clinical examination, ABI, and DUS within the first month.

Consider continued surveillance at 3 and 6 months

Repeat DUS if deteriorating clinical vascular examination, return of rest pain, non-healing wounds, or new tissue loss

### Mesenteric disease:

Screening: Only if symptomatic

#### Surveillance after angioplasty, stent, or bypass:

Clinical follow-up and baseline DUS at 1 month after procedure, 6 months, 12 months, and annually thereafter

If symptoms recur, then contrast imaging

For celiac axis, PSV >370cm/sec or substantial increase from post-treatment baseline PSV

For SMA, PSV >420cm/sec or substantial increase from post-treatment baseline PSV

For IMA, substantial increase from post-treatment baseline PSV

### Renal artery stenosis:

#### Screening:

Only if symptomatic (specifically, intervention is currently only recommended if the uncontrolled hypertension continues despite multiple medications and results in end-organ damage)

#### Surveillance after renal artery angioplasty, stent, endarterectomy, bypass:

Clinical follow-up and duplex within 1 month of the procedure, 6 months, 12 months, and annually thereafter

Contrast imaging indicated if: kidney length decreases by >1cm, PSV 280cm/s and above OR a significant increase from post-treatment baseline PSV, or renal-aortic ratio 4.5 or above

Provider decision support 7/18/2023

Dr Lundgen

